The Experts below are selected from a list of 180 Experts worldwide ranked by ideXlab platform
Du Yan - One of the best experts on this subject based on the ideXlab platform.
-
Relationship between Platelet Activation and Cor Pulmonale
Journal of Fujian Medical University, 2001Co-Authors: Du YanAbstract:Objective\ To investigate the relationship between the platelet activation and Cor Pulmonale.\ Methods\ Plasma concentration of platelet\|activating markers CD\-\{62P\} and P\-\{10\} on platelet surface were assayed using ELISA and FCM, patient's blood gas and pulmonary functions were also analysed.\ Results\ The patients of Cor Pulmonale had abnormal platelet activation, as compared with that in control, with remarkable difference(P0.01).\ The level of plateler activation was negatively related with that of PaO\-2 and pulmonary functions significantly.\ Conclusion\ There is an abnormal platelet activation in Cor Pulmonale, especially when the condition worsened.\ It is valuable to treat Cor Pulmonale using platelet activation controlling drug and coagulant.\;
Richard A. Matthay - One of the best experts on this subject based on the ideXlab platform.
-
Cor Pulmonale: an overview.
Seminars in respiratory and critical care medicine, 2003Co-Authors: Marie Budev, Alejandro C. Arroliga, Herbert P. Wiedemann, Richard A. MatthayAbstract:Chronic Cor Pulmonale involves the enlargement of the right ventricle as a result of pulmonary hypertension due to pulmonary disorders involving the lung parenchyma, bellows function, or ventilatory drive. The right ventricular hypertrophy that occurs in chronic Cor Pulmonale is a direct result of chronic hypoxic pulmonary vasoconstriction and subsequent pulmonary artery hypertension, leading to increased right ventricular work and stress. We discuss methods by which hypoxic vasoconstriction and reduction in the pulmonary vascular bed lead to the development of pulmonary artery hypertension. This article reviews the interaction of the pulmonary vasculature and right ventricle in the non-diseased state as well as during disease exacerbations. Ventricular dependence and its contribution to the pathophysiology of right ventricular failure are also reviewed. In addition, we provide an overview of specific disease states that can result in the development of chronic Cor Pulmonale including chronic obstructive pulmonary disease (COPD), interstitial lung disease, sleep apnea, alveolar hypoventilation disorders, and primary pulmonary hypertension. We also review the current diagnostic studies used to evaluate and study Cor Pulmonale.
-
Pulmonary hypertension and Cor Pulmonale in COPD.
Seminars in respiratory and critical care medicine, 2003Co-Authors: Teofilo L. Lee-chiong, Richard A. MatthayAbstract:Pulmonary artery hypertension (PAH) is the primary cardiovascular complication encountered in chronic obstructive pulmonary disease (COPD). Cor Pulmonale can range clinically from mild changes in right ventricular function to frank right heart failure. The prevalence of PAH increases as COPD worsens, and the development of PAH and Cor Pulmonale appears to affect survival of patients with COPD. Potential causes proposed to explain the development of PAH in COPD include gas exchange abnormalities, destruction of the pulmonary vascular bed, alterations in respiratory mechanics, changes in intrinsic pulmonary vessel tone, and increased blood viscosity. Standard clinical evaluation, including history, physical examination, spirometry, electrocardiography, and chest radiography, is generally inadequate in identifying right ventricular dysfunction. Noninvasive techniques, such as echocardiography, radionuclide ventriculography, and magnetic resonance imaging, have largely replaced invasive pulmonary artery catheterization in the initial assessment of Cor Pulmonale. The goals of therapy consist of attenuation of PAH, enhancement of right ventricular function, alleviation of clinical symptoms, and improvement in survival. The agents that have been most extensively evaluated for these purposes include oxygen, vasodilators, theophylline, and inotropic medications.
Joseph M Guileyardo - One of the best experts on this subject based on the ideXlab platform.
-
clinical and morphologic features of acute subacute and chronic Cor Pulmonale pulmonary heart disease
American Journal of Cardiology, 2015Co-Authors: William C Roberts, Alexis E Shafii, Paul A Grayburn, Matthew R Weissenborn, Randall L Rosenblatt, Joseph M GuileyardoAbstract:Described are certain clinical and morphologic features of one patient with acute , another with subacute , and one with chronic Cor Pulmonale. All 3 had evidence of severe pulmonary hypertension. The patient with acute Cor Pulmonale 4 days after Coronary bypass for unstable angina pectoris suddenly developed severe breathlessness with cyanosis and had fatal cardiac arrest and necropsy disclosed massive pulmonary embolism. The patient with subacute Cor Pulmonale had severe right-sided heart failure for 5 weeks and necropsy disclosed microscopic-sized neoplastic pulmonary emboli from a gastric carcinoma without parenchymal pulmonary metastases. The patient with chronic Cor Pulmonale had evidence of right-sided heart failure for years, the result of primary or idiopathic pulmonary hypertension almost certainly present from birth because the pattern of elastic fibers in the pulmonary trunk was that seen in newborns where the pressure in the pulmonary trunk and ascending aorta are similar. The patient with chronic Cor Pulmonale had plexiform pulmonary lesions indicative of irreversible pulmonary hypertension. Neither the acute nor the subacute patient had chronic pulmonary vascular changes. All 3 patients had dilated right ventricular cavities and non-dilated left ventricular cavities and only the patient with chronic Cor Pulmonale had right ventricular hypertrophy.
Paula Anderson - One of the best experts on this subject based on the ideXlab platform.
-
Cor Pulmonale in cystic fibrosis.
Seminars in respiratory and critical care medicine, 2003Co-Authors: Michael A. Eckles, Paula AndersonAbstract:Cystic fibrosis is a common autosomal recessive disorder that is associated with a defective chloride transport channel in epithelial cells. The discovery of the cystic fibrosis gene in 1989 has led to a better understanding of the pathophysiology of the disease and the development of more effective therapeutic interventions. Chronic recurrent lung infections, pancreatic exocrine insufficiency, and elevated sweat chloride levels are hallmarks of the disease. Survival of patients with cystic fibrosis is steadily improving and most patients survive into adulthood. As lung disease progresses, secondary pulmonary hypertension and Cor Pulmonale are likely to develop. Pulmonary hypertension is Correlated with the degree of hypoxemia and may be associated with increased mortality. The goal of therapy of Cor Pulmonale in cystic fibrosis is to Correct hypoxemia and lower the elevated pulmonary artery pressures. This is best achieved by supplemental oxygen and aggressive treatment of the pulmonary disease with antibiotics and airway clearance techniques. It is also important to assess oxygenation during sleep and exercise. Bilateral lung transplantation is a treatment option for patients with end-stage lung disease, even in the presence of Cor Pulmonale.
Joseph Reichel - One of the best experts on this subject based on the ideXlab platform.
-
primary pulmonary hypertension and Cor Pulmonale
Cardiology in Review, 2002Co-Authors: Stuart G Lehrman, Patricia Romano, William H Frishman, Amber Rashid, Jay B Dobkin, Joseph ReichelAbstract:Primary pulmonary hypertension and Cor Pulmonale represent forms of precapillary pulmonary hypertension due to intrinsic lung disease. In the case of primary pulmonary hypertension, this is due to disease of the pulmonary vasculature while Cor Pulmonale is related to diseases of the pulmonary vasculature, airways, or interstitium. Patients present with signs and symptoms of right ventricular dysfunction and low cardiac output including dyspnea, chest pain and peripheral edema. Therapy is directed at the underlying disease and may include supplemental oxygen for diseases causing chronic hypoxemia and anticoagulation for thrombotic disease. Vasodilator therapy has variable efficacy for pulmonary vascular disorders. Postacyclin by continuous infusion has been a major advance in the therapy of primary pulmonary hypertension and has prolonged survival and delayed the need for lung transplantation. Bosentan, an endothelin receptor blocking agent is the first oral medication approved for the therapy of pulmonary hypertension.